|1.||Shirai, T: 4 articles (10/2001 - 03/2000)|
|2.||Asamoto, M: 4 articles (10/2001 - 03/2000)|
|3.||Jones, Kathryn J: 3 articles (07/2008 - 06/2002)|
|4.||Tanzer, Lisa: 3 articles (07/2008 - 06/2002)|
|5.||Rozan, Pascale: 3 articles (02/2008 - 12/2007)|
|6.||Messaoudi, Michaël: 3 articles (02/2008 - 12/2007)|
|7.||Hidalgo, Sophie: 3 articles (02/2008 - 12/2007)|
|8.||Bisson, Jean-François: 3 articles (02/2008 - 12/2007)|
|9.||Imaida, K: 3 articles (10/2001 - 03/2000)|
|10.||Takahashi, S: 3 articles (10/2001 - 05/2001)|
|1.||Body Weight (Weight, Body)
12/01/2008 - "Males born to mothers treated with 30 mg testosterone propionate twice weekly from d 30 to 90 and with 40 mg testosterone propionate from d 90 to 120 of pregnancy (T-males) showed a significant reduction (P < 0.05) in body weight, scrotal circumference, and sperm count compared with control males. "
04/01/2013 - "Testosterone propionate was administered intramuscularly, once a week at a dose of 4 mg and 8 mg per kilogram of body weight for 15 days and for 15 weeks. "
02/01/2002 - "When testosterone propionate (10 microg/g body weight) was injected twice a day into mice which had been castrated on day 10, 30 or 60, the increases in apoptotic indices of the head, body and tail of the epididymis were completely inhibited. "
04/01/1999 - "We studied six groups of mice submitted to different treatments as follows: treated with testosterone propionate (0.1 mg/10 g body weight for 15 consecutive days), castrated and the respective control mice. "
04/01/1996 - "Rats of both genders were gonadectomized or injected with testosterone propionate within 24 hr of birth and the HPA response to 3 g/kg body weight alcohol was tested in adulthood (postpubertal period). "
04/01/1992 - "The skin tumorigenic efficacy of MNU was dependent on the time between the start of the testosterone propionate treatment and carcinogen administration: MNU injection after 48-50 or 60-63 h induced skin tumors in 17-21% of Wistar rats, whereas injection after 72-74 h induced a 48% incidence. "
03/04/2008 - "The addition of testosterone propionate does not affect tumor incidence in such rats. "
10/15/1996 - "Testosterone propionate (TP) treatment prevented LNCaP 104-R2 tumor growth and caused regression of established tumors in these mice. "
01/01/1993 - "The usefulness of transabdominal ultrasonography in the diagnosis of 3,2'-dimethyl-4-aminobiphenyl- and testosterone propionate-induced tumors of the urogenital organs was evaluated in F344 rats. "
03/01/1990 - "Hypothyroid mice bearing thyrotropic tumors were treated with testosterone propionate, 150 micrograms/100 g BW, sc, for 11 days. "
|3.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
07/01/2012 - "The present study was conducted to evaluate the effect of a fraction of macroporous resin (FMR), a bioactive component of Smilax china L., on benign prostatic hyperplasia (BPH) in castrated rats induced by testosterone propionate. "
01/01/2012 - "In this study, we investigated the effects of Yukmijihwang-tang water extract (YJT) on the development of benign prostatic hyperplasia (BPH) using a rat model of testosterone propionate (TP)-induced BPH. "
07/01/2012 - "inhibits testosterone propionate-induced prostatic hyperplasia in castrated rats."
10/01/2002 - "An experimental model of prostatic hyperplasia of castrated male mice induced by testosterone propionate was made. "
03/01/2004 - "Prostatic hyperplasia was induced by testosterone propionate in mice and castrated rats and by transplantation of homologous strain fetal mice urogenital sinus in mice. "
|4.||Vulvar Lichen Sclerosus
07/01/1994 - "Comparison between 2% testosterone propionate and petrolatum ointment in the treatment of vulvar lichen sclerosus in a randomized, double-blind, controlled clinical study. "
01/01/1998 - "Clobetasol dipropionate 0.05% versus testosterone propionate 2% topical application for severe vulvar lichen sclerosus."
04/01/1996 - "To test this hypothesis, five women with vulvar lichen sclerosus received topically either dihydrotestosterone or testosterone propionate in a double-blind cross-over study. "
02/01/1992 - "Thumb nails with asymptomatic red lunulae were noted in a 54-year-old woman with testosterone propionate-responsive vulvar lichen sclerosus et atrophicus of 4 years' duration and localized vitiligo that had been treated with topical corticosteroids for 15 months. "
04/01/1996 - "Testosterone propionate has been shown repeatedly to be effective in the treatment of vulvar lichen sclerosus, yet studies of androgens in serum of women with untreated vulvar lichen sclerosus suggested an abnormal activity of 5-alpha reductase in these patients. "
|5.||Breast Neoplasms (Breast Cancer)
05/01/1965 - "ANTITUMOR EFFICACY OF NORANDROLONE PHENPROPIONATE COMPARED WITH TESTOSTERONE PROPIONATE IN ADVANCED BREAST CANCER."
06/28/1963 - "[COMPARATIVE METHODICAL STUDY OF TESTOSTERONE PROPIONATE AND DELTA-1-TESTOLACTONE IN THE TREATMENT OF ADVANCED BREAST CANCER. "
01/01/1970 - "[17-ketosteroid changes in breast cancer during testosterone propionate treatment]."
06/22/1964 - "TESTOSTERONE PROPIONATE THERAPY IN BREAST CANCER."
01/01/1964 - "COMPARATIVE STUDY OF 6-DEHYDRO-17ALPHA-METHYLTESTOSTERONE AND TESTOSTERONE PROPIONATE IN HUMAN BREAST CANCER."
|5.||Progesterone Receptors (Progesterone Receptor)
|8.||salicylhydroxamic acid (SHAM)
|5.||Acupuncture Points (Acupuncture Point)